AstraZeneca PLC ADR closed 22.59% below its 52-week high of $87.68, which the company achieved on August 30th.

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

AstraZeneca PLC ADR closed 23.70% below its 52-week high of $87.68, which the company reached on August 30th.

A unit of AstraZeneca Plc is facing a new antitrust suit claiming the company monopolized the market for a blood disorder ...

We recently published a list of 10 Best UK Stocks to Buy According to Billionaires. In this article, we are going to take a ...

Shares of AstraZeneca PLC (LON:AZN – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat ...

VANCOUVER, BC / ACCESS Newswire / April 24, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned ...

The partnership, now in its second year, features a limited-edition T-shirt and the Body Check Cup in order to encourage more cancer screenings.

Results of Annual General Meeting held on 11 April 2025 AstraZeneca PLC announced the results of ... capital Votes withheld 1 To receive the Company's Accounts, the Reports of the Directors ...

a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today announced it has entered into a definitive agreement to be acquired by ...